{"id":53614,"date":"2025-07-10T08:14:08","date_gmt":"2025-07-10T08:14:08","guid":{"rendered":"https:\/\/www.europesays.com\/us\/53614\/"},"modified":"2025-07-10T08:14:08","modified_gmt":"2025-07-10T08:14:08","slug":"juniper-genomics-debuts-world-first-whole-genome-and-transcriptome-test","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/53614\/","title":{"rendered":"Juniper Genomics debuts ‘world first’ whole-genome and transcriptome test"},"content":{"rendered":"

Backed by $4.6M in seed funding, <\/strong>Juniper is looking to define a new clinical standard of care for IVF genetic testing<\/p>\n

Juniper Genomics<\/strong><\/a>, a healthtech company pioneering a new standard of care in IVF, has announced its public launch alongside a 4.6 million USD seed round led by Company Ventures, with participation from Innospark Ventures, MBX Capital, Amboy Street Ventures, Dria Ventures, and Blue Collective.<\/p>\n

Founded by experts in genomics, reproductive medicine, and bioethics\u2014Jeremy Grushcow, PhD, JD (CEO), Carolyn Quinlan, MSc (VP of Bioethics), and Dr. Lee Shulman (Medical Director), a leading clinical geneticist and professor of obstetrics and gynecology, Juniper is on a mission to help patients shorten their IVF journey by offering more clarity and confidence on the first transfer.<\/p>\n

Juniper\u2019s proprietary platform combines whole genome and transcriptome sequencing with trio analysis, including both biological parents, to provide the most complete, clinically-relevant, and ethically responsible insights into each embryo\u2019s health.<\/p>\n

Juniper\u2019s single test replaces almost all existing forms of preimplantation genetic testing, and adds analysing thousands of clinically relevant genetic variants linked to IVF failure, miscarriage, and medical conditions after birth. The result is the clearest, most detailed, and actionable view of embryo health and viability available today.<\/p>\n

Unlike most current testing, Juniper does not rely on polygenic or genetic risk scores. Instead, Juniper screens for specific genetic changes known to cause adverse pregnancy outcomes and serious health conditions. Polygenic risk scores assess fewer than 1,000 data points across the genome to identify statistical associations with disease risk in populations, but they do not predict or determine outcomes for individual embryos.\u00a0<\/p>\n

\u201cThe IVF journey can be emotionally exhausting and financially overwhelming\u2014and the current standard of care for embryo testing has a low success rate that often leaves patients with more questions than answers,\u201d said Jeremy Grushcow, PhD, JD, Founder and CEO of Juniper Genomics. \u201cIt\u2019s important for people to know that failed transfers aren\u2019t anyone\u2019s fault\u2014most embryos simply aren\u2019t viable. We can do better by improving the chances of success on the very first try. We work in partnership with IVF clinicians\u00a0 to pair cutting-edge science with rigorous ethical standards, ensuring families receive clear, responsible, and compassionate care every step of the way.\u201d<\/p>\n

Juniper is currently rolling out in early adopter clinics across North America, and their testing process integrates seamlessly into the existing IVF workflow. Around day 5 or 6 of embryo development, a standard biopsy is taken from each embryo and paired with a blood draw from each parent. Juniper then analyses millions of genetic markers, far beyond what traditional platforms capture, to assess embryo viability with unprecedented depth and accuracy.<\/p>\n

\u201cJuniper is addressing one of the most emotionally and financially challenging aspects of healthcare with a solution that is both scientifically advanced and deeply compassionate,\u201d said Margaret Davidson, Principal at Company Ventures. \u201cTheir approach has the potential to establish a new benchmark in IVF, combining world-class science with a strong commitment to ethics, equity, and an exceptional team driving it forward.\u201d<\/p>\n

With its seed funding, Juniper Genomics says it plans to expand its commercial reach, grow its bioinformatics and clinical teams, and continue growing its platform through ongoing research partnerships.<\/p>\n

Like this:<\/p>\n

Like Loading…<\/p>\n

<\/p>\n

\n\tRelated<\/p>\n","protected":false},"excerpt":{"rendered":"Backed by $4.6M in seed funding, Juniper is looking to define a new clinical standard of care for…\n","protected":false},"author":3,"featured_media":53615,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[39839,815,39840,39841,159,67,132,68],"class_list":{"0":"post-53614","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-femtech","9":"tag-genetics","10":"tag-ivf","11":"tag-juniper-genomics","12":"tag-science","13":"tag-united-states","14":"tag-unitedstates","15":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114827943321003150","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/53614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=53614"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/53614\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/53615"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=53614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=53614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=53614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}